DalsnaFinance › IPOs › Drugs Made In America Acquisition II Corp. IPO
Drugs Made In America Acquisition II Corp. completed its initial public offering on NASDAQ on September 25, 2025, pricing at $10.00 a share.
| Ticker | DMIIU |
|---|---|
| Exchange | NASDAQ |
| Status | Completed |
| Listing date | September 25, 2025 |
| Offering price | $10.00 |
| Shares offered | 50,000,000 |
| Total raised | $500M |
Drugs Made In America Acquisition II Corp. sold 50,000,000 shares at $10.00 each on NASDAQ. Multiplied out, that is $500 million in gross proceeds, the figure before underwriting discounts and offering expenses, and it agrees with the $500 million total recorded for the deal.
Measured by money raised, Drugs Made In America Acquisition II Corp. was the 46th largest of 473 completed IPOs with a recorded deal size that this site tracks since October 5, 2024. It is one of 46 deals in that window to raise $500 million or more. The median deal in the same window raised $200 million, so this one was about 2.5 times the typical size.
Among the 342 listings on NASDAQ alone, it is the 23rd largest.
September 2025 saw 28 completed IPOs in the site's data; by amount raised, Drugs Made In America Acquisition II Corp. was the 7th largest of the 28 deals with a recorded size.
Its $10.00 offer price was tied for the 146th highest (level with 259 other listings) of the 479 listings in the window with a recorded price. A share price on its own says nothing about a company's value; it depends on how many shares exist.
Source: SEC EDGAR filings for Drugs Made In America Acquisition II Corp.. This page is general information, not investment advice.